I think it's important to note that despite the title of the...

I think it's important to note that despite the title of the trial and its similarity to a previous radiation trial of radiation plus alpelisib on PIK3CA mutated cancers outside the brain, this trial will be looking for responses from brain cancers with any of the following mutations:

PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3C2G, PIK3C3, INPP4A, INPP4B, INPPL1, INPP5D, PTEN, AKT1, AKT2, AKT3, and MTOR.

This will encompass a much larger percentage of cases, but as such, it may also include mutations that will not respond to paxalisib. I think the importance of this study lies in finding out exactly how many different types of mutations can be targeted by paxalisib and, therefore, what the total addressable market would be.